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Abstract : Autosomal dominant polycystic kidney disease (ADPKD) develops into end-stage kidney disease by 
65 years of age in an estimated 45%-70% of patients. Recent trials revealed that tolvaptan inhibits disease pro-
gression both in early-stage or late-stage ADPKD ; however, stratified analysis showed a difference of favorable 
factors correlated with tolvaptan efficacy between early-stage and late-stage ADPKD. Thus, we examined the effi-
cacy of tolvaptan in ADPKD with a wide range of estimated glomerular filtration rates (eGFR). We enrolled 24 pa-
tients with eGFR 35.3 (28.0-65.5) ml / min / 1.73m2 and evaluated treatment effect as ΔΔeGFR (ml / min / 1.73m2 / year) 
or ΔΔtotal kidney volume (TKV) (% / year) that was calculated as post-treatment annual change - pre-treatment 
annual change. Pre ΔeGFR was significantly low in eGFR responders, defined as ΔΔeGFR > 0 ml / min / 1.73m2 / year. 
In eGFR responders, pre ΔeGFR, post ΔeGFR, eGFR, TKV, and proteinuria were significantly correlated with 
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INTRODUCTION
 
Autosomal dominant polycystic kidney disease (ADPKD) is 
the most common hereditary kidney disease caused by muta-
tions in the genes encoding polycystin 1 (PKD1) or polycystin 
2 (PKD2). Progression of the disease is inexorable with an esti-
mated 45%-70% of patients developing end-stage kidney disease 
by the age of 65. Mutations in PKD1 or PKD2 elevate the levels 
of intracellular adenosine 3’, 5’-cyclic monophosphate (cAMP) (1, 
2). The high intracellular cAMP promotes fluid secretion and 
renal tubular cell proliferation (3), which results in cyst forma-
tion. Vasopressin promotes kidney-cyst cell proliferation and 
fluid secretion into cysts by means of upregulation of cAMP in 
renal tubular cells. Genetic elimination of circulating vasopres-
sin or pharmacological V2 receptor blockade inhibits disease pro-
gression in animal models orthologous to human ADPKD (4-6). 
Phase 3, randomized, double-blind, placebo-controlled trials 
have revealed that tolvaptan, vasopressin V2-receptor blocker, 
reduces cyst burden and protects kidney function compared with 
placebo both in patients with early-stage or late-stage ADPKD 
(7-9). Interestingly, stratified analysis in these studies showed 
that a difference of favorable factors correlated with tolvaptan 
efficacy on kidney function or volume between early-stage and 
late-stage ADPKD. TEMPO 3 : 4, a 3-year trial that examined 
patients with early-stage ADPKD with estimated glomerular 
filtration rate (eGFR) > 60 ml / min / 1.73m2, clarified that tolvap-
tan was more effective in more advanced patients with age ≧ 35 
years or total kidney volume (TKV) ≧ 1500 ml. In contrast, 
the REPRISE trial proved the efficacy and safety of tolvaptan 
in late-stage patients with eGFR 25 to 65 ml / min / 1.73m2, 
wherein tolvaptan was more effective in early-stage patients 
with age ≦ 55 years or with chronic kidney disease (CKD) stage 
3a (eGFR 45 to 59 ml / min / 1.73m2). In practical clinic settings, 
we often administer tolvaptan in patients with CKD stage 1-4 
and observe that the response to tolvaptan varies clinically. 
Some patients present adverse effects of tolvaptan. Clarifying 
the determinant of the responsiveness to tolvaptan is clinically 
crucial to treat patients more efficiently. Therefore, we examined 
the clinical characteristics associated with tolvaptan efficacy on 




We administered tolvaptan to 34 patients with ADPKD in our 
hospitals between May 2015 and December 2017 and enrolled 24 
patients who were followed for more than 1 year after tolvaptan 
administration in this study. During the follow-up period, we 
excluded four patients because of discontinuation of tolvaptan 
due to liver dysfunction and excluded one patient due to end-stage 
kidney disease. We also excluded patients whose annual eGFR 
change for more than 1 year before tolvaptan initiation was 
unknown or patients with eGFR > 90 ml / min / 1.73m2 at tolvaptan 
administration. eGFR was calculated from serum creatinine and 
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(ml / min / 1.73m2) = 194 × Age-0.287 × Creatinine (mg / dL)-1.094 
(× 0.739 if female). TKV was calculated by the ellipsoid rota-
tion method. Pre ΔeGFR (ml / min / 1.73m2 / year) and pre ΔTKV 
(% / year) were defined as the annual eGFR change and the an-
nual TKV change before tolvaptan administration, respectively. 
Post ΔeGFR (ml / min / 1.73m2 / year) was defined as the annual 
eGFR change for 1 year after tolvaptan initiation. Patients 
with tolvaptan administration frequently show the initial drop 
of eGFR, therefore we started to follow post ΔeGFR one month 
after tolvaptan initiation. One year after tolvaptan initiation, we 
re-evaluated TKV, and post ΔTKV (% / year) was defined as the 
annual TKV change. ΔΔeGFR was calculated as follows : ΔΔeG-
FR (ml / min / 1.73m2 / year) = post ΔeGFR – pre ΔeGFR. ΔΔTKV 
was calculated as follows : ΔΔTKV (% / year) = post ΔTKV – pre 
ΔTKV. We evaluated the response to tolvaptan in ADPKD as 
ΔΔeGFR and ΔΔTKV. Unfortunately, we were not able to measure 
TKV 1 year after tolvaptan initiation in 1 patient, thus statistical 
analysis of ΔΔTKV was performed in total 23 patients. We evalu-
ated TKV and eGFR at tolvaptan initiation and urine osmolality 
after tolvaptan initiation. We measured mean blood pressure and 
urine volume during hospitalization for tolvaptan administration. 
Tolvaptan dosage was adjusted in accordance with patient’s con-
sent and tolerability and corrected by body surface area. 
Statistical analysis
The results are shown as mean ± standard deviation, as 
number (%) or as median (interquartile range) if skewed. A test 
for normality was performed using the Kolmogorov-Smirnov 
test. P value was calculated with student’s t-test in parametric 
variables or Mann -Whitney’s U test was used in non-parametric 
variables between two groups. A p value ≦ 0.05 was considered 
significant. Statistical analyses were performed with IBM SPSS 
statics.
Ethical approval 
This study was approved by the Ethics Committee of Tokushima 
University Hospital (No.3105-2) and Kawashima Hospital 
(No.0395), and was performed in compliance with the Helsinki 
Declaration. We provided all individual patients with the option 
to opt out of participation.
RESULTS
Baseline characteristics of enrolled patients
In this study, we enrolled 24 patients (male : 17 [70.8%], 
female : 7 [29.2%]) with ADPKD treated with tolvaptan in 
Tokushima University Hospital or Kawashima Hospital. Base-
line characteristics are shown in Table 1. Their mean age was 
52.2 ± 8.8 years. The median eGFR and TKV after tolvaptan ad-
ministration were 35.3 (28.0-65.5) ml / min / 1.73m2 and 2.1 (1.4-
2.9) L, respectively, thus indicating that patients with late-stage 
ADPKD were examined in this study. The mean post ΔeGFR 
was -1.8 ± 4.2 ml / min / 1.73m2 / year, which was significantly im-
proved by tolvaptan (p < 0.05*, the mean pre ΔeGFR : -4.8 ± 2.9 
ml / min / 1.73m2 / year). The mean post ΔTKV (-4.0 ± 13.1 % / year) 
was significantly decreased by tolvaptan (p < 0.01**, the median 
pre ΔTKV : 9.9 [5.8-14.7] % / year) (Figure 1). These data suggest 
tolvaptan is effective for preserving kidney function and for TKV 
reduction during 1 year.
Comparison between responders and non-responders in ΔΔeGFR 
or ΔΔTKV
Initially, we compared clinical characteristics between re-
sponders and non-responders (Table 2). We defined a respond-
er as follows : ΔΔeGFR > 0 ml / min / 1.73m2 / year or ΔΔTKV 
Table 1.　Baseline characteristics of enrolled participants
Data are presented as mean ± standard deviation, as number 
(%) or as median (interquartile range) if skewed. aData 
are shown at hospitalization for tolvaptan administration. 
ADPKD, Autosomal dominant polycystic kidney disease ; BP, 
blood pressure; eGFR, estimated glomerular filtration rate; 
TKV, total kidney volume; BSA, body surface area.
Figure 1.　The effect of tolvaptan on ΔeGFR and ΔTKV
Pre ΔeGFR (ml / min / 1.73m2 / year) and pre ΔTKV (% / year) were 
defined as the annual eGFR change and the annual TKV change 
before tolvaptan administration, respectively. Post ΔeGFR 
(ml / min / 1.73m2 / year) and post ΔTKV (% / year) were defined as the 
annual eGFR and TKV change for 1 year after tolvaptan initiation, 
respectively. The mean post ΔeGFR was -1.8 ± 4.2 ml / min / 1.73m2 / year, 
which was significantly improved (p < 0.05*, the mean pre ΔeGFR : 
-4.8 ± 2.9 ml / min / 1.73m2 / year). The mean post ΔTKV (-4.0 ± 13.1 
% / year) was significantly decreased (p < 0.01**, the median pre 
ΔTKV : 9.9 [5.8-14.7] % / year). eGFR, estimated glomerular filtration 
rate; TKV, total kidney volume.
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< -5% / year. The responders in ΔΔeGFR (N = 14) presented a 
significant difference in proteinuria (p < 0.05*), pre ΔeGFR 
(p < 0.01**), post ΔeGFR (p < 0.01**), and ΔΔeGFR (p < 0.01**). 
With respect to ΔΔTKV, the responders (N = 15) showed a 
significant difference in post ΔTKV (p < 0.01**) and ΔΔTKV 
(p < 0.01**). There was no difference in blood pressure, TKV, 
eGFR, or urine osmolality between the responders and the 
non-responders. Interestingly, these data indicated that the 
effect of tolvaptan on eGFR and TKV was independent and that 
the rate of eGFR change before treatment may be the index of 
responder in eGFR.
Correlation of ΔΔeGFR or ΔΔTKV with clinical characteristics in 
the responder group
Furthermore, we examined the correlated factors with ΔΔeGFR 
or ΔΔTKV in the responders (Table 3). ΔΔeGFR significantly cor-
related with proteinuria (ρ = -0.36, p < 0.05*), eGFR at tolvaptan 
initiation (ρ = 0.77, p < 0.01**), TKV at tolvaptan initiation 
(ρ = -0.59, p < 0.05*), pre ΔeGFR (ρ = -0.91, p < 0.01**), and post 
ΔeGFR (ρ = 0.75, p < 0.01**) in the ΔΔeGFR responder group, 
wherein eGFR at tolvaptan initiation was significantly cor-
related with TKV at tolvaptan initiation (ρ = -0.78, p < 0.01**). 
ΔΔTKV showed significant correlation with hypertension history 
Table 2.　Comparison between responders and non-responders in ΔΔeGFR and ΔΔTKV
Data are presented as mean ± standard deviation, as number (%) or as median (interquartile range) if skewed. aData are shown at 
hospitalization for tolvaptan administration. bTKV 1 year after tolvaptan initiation were not measured in 1 patient, thus statistical 
analysis of ΔΔTKV was performed in total 23 patients. P value was calculated with student’s t-test in parametric variables or 
Mann -Whitney's U test was used in non-parametric variables. ADPKD, Autosomal dominant polycystic kidney disease ; BP, blood 
pressure ; eGFR, estimated glomerular filtration rate ; TKV, total kidney volume ; BSA, body surface area.
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(ρ = 0.67, p < 0.05*), proteinuria (ρ = 0.65, p < 0.05*), TKV at tol-
vaptan initiation (ρ = 0.63, p < 0.05*), and post ΔTKV (ρ = 0.76, 
p < 0.01**) in the ΔΔTKV responder group. In this group, TKV 
significantly correlated with eGFR (ρ = -0.70, p < 0.01**).
 
DISCUSSION
This longitudinal observational study investigated the clinical 
characteristics of the 1-year therapeutic efficacy of tolvaptan 
in Japanese patients with ADPKD. Our study enrolled pa-
tients with a wide range of kidney function, CKD stage 2-4, 
and evaluated the treatment effect of tolvaptan as ΔΔeGFR or 
ΔΔTKV before and 1 year after tolvaptan administration, where-
in we examined clinical factors associated with tolvaptan effica-
cy. The current study revealed that pre ΔeGFR was very relevant 
to the efficacy of tolvaptan on kidney function. In the ΔΔeGFR 
responder group, the mean pre ΔeGFR was significantly lower 
and pre ΔeGFR was significantly correlated with ΔΔeGFR, 
thus suggesting that ADPKD patients with rapid GFR decline 
clinically show a good response to tolvaptan. The poor prognostic 
markers of kidney function in ADPKD have been reported as 
follows : PKD1 gene mutation, younger age at diagnosis, male 
gender, hypertension, increased left ventricular mass, three or 
Table 3.　Correlation of ΔΔeGFR and ΔΔTKV with clinical characteristics
P value is calculated with spearman’s correlation coefficient test by rank test. ADPKD, Autosomal dominant polycystic kidney 
disease ; BP, blood pressure ; eGFR, estimated glomerular filtration rate ; TKV, total kidney volume ; BSA, body surface area.
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more pregnancies, and the development of gross hematuria at a 
younger age (10, 11). The TEMPO trial revealed that tolvaptan 
was more effective in patients with PKD1 mutation compared 
to that in patients with PKD2 mutation. These data indicate 
that patients with PKD1 mutation have poor kidney prognosis 
but have better response to tolvaptan. The ΔΔeGFR responder 
group with rapid decline of GFR in the current study may be pa-
tients with PKD1 mutation, although we did not examine their 
genotype. Genotype analyses in ADPKD patients are out of the 
application range of health insurance treatment in Japan ; thus, 
pre ΔeGFR may be a predictive factor of therapeutic efficacy on 
GFR in a practical clinic setting. 
Furthermore, ΔΔeGFR in the responder group was positively 
correlated with eGFR at tolvaptan initiation and negatively 
correlated with TKV at tolvaptan initiation, wherein eGFR 
and TKV at tolvaptan initiation showed the significant inverse 
correlation. In ADPKD, kidney enlargement due to cyst devel-
opment results in the decline of GFR. These data mean that the 
effect of tolvaptan on kidney function decreases in patients with 
late-stage ADPKD. Meiher et al reported that initiation of vaso-
pressin V2 receptor antagonist at an advanced stage of disease 
lacked renoprotective effects in the Pkd1-deletion mouse model 
(12). In patients with advanced ADPKD, Tolvaptan has presum-
ably less effect on GFR because of the loss of functional nephron 
or thick-walled cyst surrounded by irreversible interstitial fibro-
sis with an associated decline in GFR (13). The results suggest 
that tolvaptan may have greater efficacy on GFR in early-stage 
ADPKD with rapid GFR decline. 
No predicting factor for the effect on TKV was identified. 
However, ΔΔTKV presented positive correlation with TKV at 
tolvaptan initiation in the responder group. The data suggest 
that patients with early-stage ADPKD have a better response 
for TKV reduction in the first year of treatment. Interestingly, 
this trend was also observed in the effect on GFR although the 
efficacy of tolvaptan on eGFR and on TKV were independent in 
this study. In the TEMPO 3 : 4 and TEMPO 4 : 4, the treatment 
effect on TKV reduction was greater in the first year of treat-
ment than in the second and third years. The reduction in TKV 
during the first year is thought to be due to inhibition of fluid 
secretion into cysts. Two short-term trials in patients with de-
creased GFR support this possible mechanism of inhibited fluid 
secretion. Irazabal et al demonstrated that the administration 
of tolvaptan over 1 week significantly reduces kidney and cyst 
volume to a greater extent than it reduces body water without 
a significant change in renal blood flow in 20 patients with 
ADPKD with mean eGFR 69.3 ± 34.8 ml / min / 1.73m2, and that 
the decrease is greater in those with eGFR > 60 ml / min / 1.73m2 
than in those with eGFR < 60 ml / min / 1.73m2 (14). In 27 patients 
with measured GFR ranging from 18 to 148 ml / min, Boertien et 
al showed that 3 weeks of therapy resulted in a similar decline 
in TKV that is greater in those with higher kidney function. In 
addition, in that study, they also showed that free-water clear-
ance per single nephron was greater in patients with decreased 
kidney function, thus indicating that tolvaptan is pharmacody-
namically effective throughout a wide range of kidney function 
in ADPKD (15). In the current study, eGFR in the ΔΔTKV 
responder group ranged from 17 to 77 ml / min / 1.73m2. These 
data suggest that the effect of tolvaptan on TKV in the first year 
can be obtained in those with a wide range of GFR depending on 
the number of residual nephrons probably due to the inhibition 
of fluid secretion.
The current study revealed that the effect of tolvaptan on 
ΔΔTKV was significantly better in patients without hyperten-
sion history at tolvaptan initiation in the ΔΔTKV responder 
group (p < 0.05*). Patients with ADPKD often develop hyper-
tension, presumably because of activation of renin-angioten-
sin-aldosterone system (RAAS) or endothelial injury (16). RAAS 
activation in ADPKD is assumed to accelerate renal cyst growth 
or fibrosis (17, 18). In addition, rigorous BP control is associated 
with a slower increase in total kidney volume (19). These results 
indicate that treatment with tolvaptan and anti-hypertensive 
therapy may additively inhibit cyst enlargement.
Previous studies have reported proteinuria in ADPKD was as-
sociated with poor kidney function (20) and kidney enlargement 
(11). In this study, patients with proteinuria showed poor efficacy 
of tolvaptan both on GFR and on TKV. However, the current 
study revealed that those with proteinuria showed the signif-
icant low eGFR and the significant large TKV which suggest 
late-stage ADPKD. We speculate that patients with proteinuria 
may present poor efficacy due to advanced ADPKD stage.
This study had certain limitations. First, the number of par-
ticipants is relatively small. However, the current study revealed 
a significant correlation between tolvaptan efficacy and a few 
clinical factors, which is in line with published literature. Sec-
ond, the current study examined 1-year tolvaptan efficacy. The 
study about long term efficacy is required for suppression of end-
stage kidney disease.
The current study revealed the clinical features of tolvaptan 
effect in ADPKD with a wide range of GFR (CKD stage 2-4). 
We consider that the annual eGFR change before tolvaptan 
treatment may be a useful marker of tolvaptan efficacy on 
kidney function and that tolvaptan should be administered in 
early-stage ADPKD with rapid GFR decline under sufficient BP 
control. We consider that our data contribute the efficient use of 
tolvaptan in ADPKD in practical clinic settings. Future studies 
with a greater number of patients could provide more significant 
results.
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